PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Fiona Collinson(St James's University Hospital), Naveen Vasudev(University of Leeds), Galina Velikova(University of Leeds), Heather Poad(University of Leeds), Gemma Carr(TU Wien), Gemma Ainsworth(University of Leeds), Sarah Brown(University of Leeds), Roz Banks(University of Leeds), James Larkin(Trinity College Dublin), Paul Nathan(Mount Vernon Hospital), Hannah Buckley(University of Leeds), Helen Howard(University of Leeds), T.B. Powles(Queen Mary University of London), Julia Brown(University of Leeds)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k